title: [Tear in retinal pigment epithelium under anti-VEGF therapy for exudative age-related macular degeneration : function recovery under intensive therapy].
abstract: This article reports the case of a 72-year-old woman with pigment epithelial detachment with occult choroidal neovascularization (CNV) in exudative age-related macular degeneration (AMD) which developed under anti-vascular endothelial growth factor (VEGF) therapy of a tear in the retinal pigment epithelium (RPE). In the area of free RPE autofluorescence was completely absent and the microperimetry in this area showed an absolute scotoma. The visual acuity was 0.1. After continuation of anti-VEGF therapy because of persistent subretinal and intraretinal fluid over 3 years an increased autofluorescence was observed and the microperimetry showed an increase in central retinal sensitivity. The central visual acuity improved to 0.5 and in this area a whitish subretinal tissue formed morphologically. In the spectral domain optical coherence tomography (SD-OCT) image this structure was hyperreflective which might suggest a certain regeneration process of the RPE under anti-VEGF-therapy.
authors.affiliation: Augenabteilung am St. Franziskus Hospital, Hohenzollernring 74, 48145, Münster, Deutschland.
authors.forename: S
authors.initials: S
authors.lastname: Bartels
authors.forename: A
authors.initials: A
authors.lastname: Barrelmann
authors.forename: B
authors.initials: B
authors.lastname: Book
authors.forename: B
authors.initials: B
authors.lastname: Heimes
authors.forename: M
authors.initials: M
authors.lastname: Gutfleisch
authors.forename: G
authors.initials: G
authors.lastname: Spital
authors.forename: D
authors.initials: D
authors.lastname: Pauleikhoff
authors.forename: A
authors.initials: A
authors.lastname: Lommatzsch
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D005122:Exudates and Transudates; D005260:Female; D006801:Humans; D000069579:Ranibizumab; D020127:Recovery of Function; D012163:Retinal Detachment / Q000139:chemically induced* / Q000473:pathology / Q000628:therapy*; D041623:Tomography, Optical Coherence / Q000379:methods*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D057135:Wet Macular Degeneration / Q000150:complications / Q000188:drug therapy* / Q000473:pathology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab
references.citation: Retina. 2008 Oct;28(8):1151-8
references.pmid: 18685542
references.citation: Am J Ophthalmol. 1989 Dec 15;108(6):683-5
references.pmid: 2596548
references.citation: Br J Ophthalmol. 2012 Sep;96(9):1211-6
references.pmid: 22826551
references.citation: Ophthalmologe. 2008 Feb;105(2):158-64
references.pmid: 17653552
references.citation: Graefes Arch Clin Exp Ophthalmol. 2007 Jul;245(7):1037-40
references.pmid: 17318562
references.citation: Ophthalmology. 2011 Dec;118(12):2447-52
references.pmid: 21872935
references.citation: Acta Ophthalmol. 2014 Feb;92(1):94-7
references.pmid: 22989199
references.citation: Retina. 2009 Mar;29(3):335-9
references.pmid: 19174716
references.citation: Br J Ophthalmol. 1988 Dec;72(12):918-20
references.pmid: 3228547
references.citation: Retina. 2008 Oct;28(9):1265-9
references.pmid: 18628724
references.citation: Eye (Lond). 2011 Sep;25(9):1181-6
references.pmid: 21701525
references.citation: Acta Ophthalmol Scand. 2007 Dec;85(8):902-3
references.pmid: 17408387
references.citation: Retina. 2007 Jun;27(5):541-51
references.pmid: 17558314
references.citation: Acta Ophthalmol. 2008 Jun;86(4):372-6
references.pmid: 18028234